The artificial intelligence solution for pharmacovigilance that facilitates the management of adverse event reports.
The "Medication Shield" technology manages in real-time adverse drug reactions (ADRs) signals by encoding them automatically into a standardized, international terminology (MedDRA) and ranks them by severity. This helps pharmacovigilance teams daily in their management of ADRs reports.
The Medication Shield identifies in real-time the drugs involved by coding them in ATC class.
Using NLP algorithms, the Medication Shield detects adverse events by coding them in MedDRA terminology.
It analyzes the seriousness level of adverse events to enable their classification and increases pharmacovigilance teams’ reactivity.
Finally, it determines the expected or unexpected nature of the ADE and its frequency of occurrence according to the drug monograph.
The Medication Shield's natural language processing (NLP) algorithms extract the terms used when reporting an adverse reaction and find its correspondence according to the MedDRA classification. The Medication Shield then analyzes whether this adverse reaction is expected, its level of severity and its frequency.
The Medication Shield unifies all the information on adverse drug events and facilitates decision-making by pharmacovigilants.
The Medication Shield integrates easily with third-party ADE management softwares. It allows pharmacovigilants to benefit from the power of the Medication Shield’s artificial intelligence while continuing to use their everyday softwares.
The Medication Shield is also used in the COVID-19 vaccination campaign in France. The integration of the Medication Shield in partnership with the ANSM facilitates on a daily basis the management of adverse event reports by the pharmacovigilance teams.
The reporting portal implemented by the French Ministry of Health allows the Regional Pharmacovigilance Centers (CRPVs) to be notified of ADRs detected by healthcare professionals (HCP), patients, or by the pharmaceutical industry.
Synapse Medicine uses its Medication Intelligence technology expertise to help Regional Pharmacovigilance Centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM) to manage ADR reports. The "Medication Shield" technology encodes ADR signals according to an international terminology (MedDRA) and ranks them by severity.
Regional Pharmacovigilance Centers can thereby benefit from an easier and faster reading of data linked to ADR reports. Synapses' technology is a valuable time-saver that allows them to focus their attention on the most complex cases.
The Medication Shield simplifies ADR signals processing and allows health authorities to detect them faster after the drug is commercialized.
Check our infographic that explains how the Medication Shield technology is integrated into the French pharmacovigilance system.
In Clinical Pharmacology & Therapeutics, a leading international scientific journal, find our latest publication on the "Medication Shield" technology: Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions.
Synapse Medicine, the French FDA (ANSM), the Pharmacology Department of the Bordeaux University Hospital, and the Pharmacoepi - Inserm U1219 BPH team of the University of Bordeaux.
Since its inception in 2017 by HCPs, Synapse Medicine has collaborated with some of the most significant french Hospitals and public health institutions.
Synapse Medicine made an unprecedented technology platform available to the COVERAGE clinical trial led by the Bordeaux University Hospital, one of the most significant clinical trials on primary care conducted during COVID-19 context.
To support mobile teams in their randomized chosen treatment administration, the platform helps physicians to check instantly whether this treatment is suitable or not with the patients' regular drug use.
A valuable time saver for HCPs, which is also increasing patients' safety.
When a drug is commercialized, it is always monitored by a pharmacovigilance system to evaluate its risks. This system involves healthcare professionals, CRPVs, and the ANSM. These monitoring activities include collecting a significant amount of data that have to be analyzed and sorted to take corrective measures if needed.
The Medication Shield technology was developed to make the management of ADR reports easier for pharmacovigilant experts.
This was made possible thanks to the collaboration of the CRPVs pharmaceutical expertise, the ANSM, and Synapse Medicines' technology, which is beneficial to the populations' safety.
Dr. Louis Letinier - Medical Director and Co-Founder Synapse Medicine
Létinier, L. et al. Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions.Clin. Pharmacol. Ther. 110, 392–400 (2021).
You can ask us any questions related to the Medication Shield technology via this form. Our team will make sure to answer your request as soon as possible.
